GenScript ProBio

GenScript ProBio is an active global CDMO/CRO subsidiary of GenScript Biotech Corporation specializing in end-to-end biopharmaceutical development and manufacturing services. It supports clients with solutions spanning drug discovery to commercial-scale production across modalities such as antibodies, recombinant proteins, cell/gene therapies—including GMP-grade plasmids/mRNAs/viral vectors—and vaccines. The company has enabled over sixty IND approvals since October 2017 and played a key role in the development/licensing of next-generation immuno-oncology assets like anti-PD‑1 NMEs now partnered with major pharma companies. Its global footprint includes facilities in the US (notably Hopewell NJ), China (Nanjing/Hong Kong/Shanghai), South Korea, and the Netherlands. The business operates at international regulatory standards including FDA/EMA/NMPA-compliant GMP capacity.